Levofloxacin Hydrochloride Capsules

This product has a broad-spectrum antibacterial effect and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, and Gram-negative bacteria such as Haemophilus influenzae, Legionella pneumophila, and Neisseria gonorrhoeae. It also has antibacterial effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and Mycoplasma pneumoniae and Chlamydia pneumoniae, but has poor effects on anaerobic bacteria and enterococci. This product is the levorotatory form of ofloxacin, and its in vitro antibacterial activity is about twice that of ofloxacin. Its mechanism of action is to inhibit the activity of bacterial DNA gyrase, prevent the synthesis and replication of bacterial DNA, and cause bacterial death.

The main ingredient of this product is: levofloxacin hydrochloride.

This product is a capsule, and the contents are off-white or light yellow powder.

This product is suitable for the following mild and moderate infections caused by sensitive bacteria: respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis and infection, pneumonia, tonsillitis (peritonsillar abscess); urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); skin and soft tissue infections: infectious impetigo, cellulitis, lymphangiitis (nodal inflammation), subcutaneous abscess, perianal abscess, etc.; intestinal infections: bacillary dysentery, infectious enteritis, salmonella enteritis, typhoid and paratyphoid; various infections in patients with sepsis, neutropenia and immunodeficiency; other infections: mastitis, trauma, burns and postoperative wound infection, abdominal infection (metronidazole can be used in combination when necessary), cholecystitis, cholangitis, bone and joint infection and ENT infection, etc.

Oral. Common dosage for adults: 1. Bronchial infection, lung infection: 0.2g (2 tablets) once, twice a day, or 0.1g (1 tablet) once, 3 times a day, for a course of 7 to 14 days. 2. Acute simple lower urinary tract infection: 0.1g (1 tablet) once, twice a day, for a course of 5 to 7 days; complicated urinary tract infection: 0.2g (2 tablets) once, twice a day, or 0.1g (1 tablet) once, 3 times a day, for a course of 10 to 14 days. 3. Bacterial prostatitis: 0.2g (2 tablets) once, twice a day, for a course of 6 weeks. Common dosage for adults is 0.3 to 0.4g (3 to 4 tablets) per day, taken in 2 to 3 times. If the infection is severe or the sensitivity of the pathogen is poor, such as Pseudomonas aeruginosa and other Pseudomonas bacterial infections, the therapeutic dose can also be increased to 0.6g (6 tablets) per day, taken in 3 times.

1. Gastrointestinal reactions: abdominal discomfort or pain, diarrhea, nausea or vomiting. 2. Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3. Allergic reactions: rash, skin itching, occasionally exudative erythema multiforme and angioneurotic edema. Photosensitivity reactions are less common. 4. Occasionally, the following may occur: (1) epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, tremors. (2) interstitial nephritis manifestations such as hematuria, fever, and rash. (3) phlebitis. (4) crystalluria, which is more common when used in high doses. (5) joint pain. 5. A small number of patients may experience elevated serum aminotransferase, elevated blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

Patients who are allergic to this product and fluoroquinolones are contraindicated.

Precautions for children: Patients under 18 years of age are prohibited. Precautions for pregnancy and lactation: 1. Women who are pregnant or may become pregnant are prohibited; 2. Women who are lactating are prohibited. Precautions for the elderly: This product is mainly excreted in the kidney fluid in its original form. Elderly patients often have impaired renal function and should be used in reduced doses as appropriate. The recommended dose for elderly patients is one tablet at a time, once every 12 hours.

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When quinolone antibiotics are used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver elimination of theophylline, a prolonged blood elimination half-life (t1/2?), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Although this product has little effect on the metabolism of theophylline, theophylline blood drug concentration should still be measured and the dose adjusted when used in combination. 3. When this product is used in combination with cyclosporine, the blood drug concentration of cyclosporine can be increased. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4. When this product is used in combination with the anticoagulant warfarin, although the anticoagulant effect of the latter is slightly enhanced, the patient's prothrombin time should also be closely monitored when used in combination. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used together, it may cause toxicity due to the increased blood concentration of this product. 6. This product can interfere with the metabolism of caffeine, thereby reducing the elimination of caffeine, prolonging the blood elimination half-life (t1/2β), and may cause central nervous system toxicity. 7. Antacids and iron preparations containing aluminum and magnesium can reduce the oral absorption of this product and should not be used together. 8. When this product is used in combination with the non-steroidal anti-inflammatory drug fenbufen, convulsions may occasionally occur, so it is not suitable for use with fenbufen.

Keep away from light and store in sealed container.

0.1g

36 months

Fujian Le’erkang Pharmaceutical Co., Ltd.

• Founded in:

  1998-03-19

• Address:

  No. 109, Meilin Road, Zhao'an Industrial Park, Zhangzhou City, Fujian Province

• Tax NO.:

  91350624611473384C

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view